Kinase inhibitors
US-2015329523-A1 · Nov 19, 2015 · US
Inhibitor of p38 MAP kinase
US11634406B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11634406-B2 |
| Application number | US-202017031190-A |
| Country | US |
| Kind code | B2 |
| Filing date | Sep 24, 2020 |
| Priority date | Feb 14, 2014 |
| Publication date | Apr 25, 2023 |
| Grant date | Apr 25, 2023 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
A compound has the following formula:The compound is a p38 MAP kinase inhibitor. The compound and its pharmaceutically acceptable salts can be used for treatment of conditions, such as inflammatory diseases.
First claim
Opening claim text (preview).
What is claimed is: 1. A method of treatment of a condition selected from exacerbation of COPD and exacerbation of asthma comprising administering to a subject in need thereof an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof, including all stereoisomers and tautomers thereof. 2. The method of claim 1 , wherein the exacerbation of COPD or exacerbation of asthma is a virally induced exacerbation. 3. The method of claim 1 , wherein the condition is exacerbation of COPD. 4. The method of claim 1 , wherein the COPD is selected from a group consisting of chronic bronchitis and emphysema. 5. The method of claim 1 , wherein the asthma is pediatric asthma. 6. The method of claim 1 , wherein the compound of formula (I) or a pharmaceutically acceptable salt thereof, including all stereoisomers and tautomers thereof is administered as a dry-powder formulation for inhalation. 7. The method of claim 6 , wherein the dry-powder formulation for inhalation comprises lactose. 8. The method of claim 1 , further comprising administering an antiviral agent. 9. The method of claim 1 , wherein the compound of formula (I) is in its free base form. 10. The method of claim 1 , wherein the compound of formula (I) is in anhydrous solid crystalline form.
Assignees
Inventors
Classifications
Artificial tears; Irrigation solutions · CPC title
Ortho-condensed systems · CPC title
Bronchodilators · CPC title
Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine · CPC title
of carboxylic acids · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11634406B2 cover?
- A compound has the following formula:The compound is a p38 MAP kinase inhibitor. The compound and its pharmaceutically acceptable salts can be used for treatment of conditions, such as inflammatory diseases.
- Who is the assignee on this patent?
- Respivert Ltd
- What technology area does this patent fall under?
- Primary CPC classification A61K9/0075. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Apr 25 2023 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 12 related publications on this page (citations in our corpus or others sharing the same primary CPC).